Targeted Drug Therapy to Overcome Chemoresistance in Triple-negative Breast Cancer

Author(s): Mamta Kumari, Praveen Thaggikuppe Krishnamurthy*, Piyong Sola

Journal Name: Current Cancer Drug Targets

Volume 20 , Issue 8 , 2020

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Triple-negative Breast Cancer (TNBC) is the most aggressive and prevailing breast cancer subtype. The chemotherapeutics used in the treatment of TNBC suffer from chemoresistance, dose-limiting toxicities and off-target side effects. As a result, conventional chemotherapeutics are unable to prevent tumor growth, metastasis and result in failure of therapy. Various new targets such as BCSCs surface markers (CD44, CD133, ALDH1), signaling pathways (IL-6/JAK/STAT3, notch), pro and anti-apoptotic proteins (Bcl-2, Bcl-xL, DR4, DR5), hypoxic factors (HIF-1α, HIF-2α) and drug efflux transporters (ABCC1, ABCG2 and ABCB1) have been exploited to treat TNBC. Further, to improve the efficacy and safety of conventional chemotherapeutics, researchers have tried to deliver anticancer agents specifically to the TNBCs using nanocarrier based drug delivery. In this review, an effort has been made to highlight the various factors responsible for the chemoresistance in TNBC, novel molecular targets of TNBC and nano-delivery systems employed to achieve sitespecific drug delivery to improve efficacy and reduce off-target side effects.

Keywords: Triple-negative breast cancer, metastasis, chemoresistance, nanocarriers, chemoresistance, drug therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Page: [559 - 572]
Pages: 14
DOI: 10.2174/1568009620666200506110850
Price: $65

Article Metrics

PDF: 31